Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
26 hedge funds and large institutions have $11.9M invested in Seelos Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.
154% more capital invested
Capital invested by funds: $4.67M → $11.9M (+$7.2M)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
8% more funds holding
Funds holding: 24 → 26 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.36M |
| 2 |
Squarepoint
New York
|
+$165K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$161K |
| 4 |
DC
Davenport & Co
Richmond,
Virginia
|
+$141K |
| 5 |
Renaissance Technologies
New York
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$468K |
| 2 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$106K |
| 3 |
Two Sigma Advisers
New York
|
-$86.3K |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$75K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$24K |
SEEL Hedge Fund Activity: Q4 2020 in Review
26 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2020, worth a combined $11.9M — up 154% from $4.67M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SEEL positions and 7 closed out — a net gain of 3 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.36M. The largest seller was CIBC World Market, exiting entirely with an estimated $468K sold.
- 26 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2020, up from 24 in Q3 2020.
- Funds reported $11.9M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2020, up 154% quarter-over-quarter.
- 10 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2020 and 7 closed out, a net change of +3 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2020 was Vanguard Group, an estimated $2.36M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2020 was CIBC World Market, an estimated $468K sold.
Based on aggregated 13F filings for Q4 2020.